Loading...
•
Mar 31, 2022
Regeneron Q1 2022 Earnings Report
Regeneron's first quarter performance was marked by revenue and earnings growth, accompanied by R&D progress.
Key Takeaways
Regeneron reported a strong first quarter in 2022, with total revenues increasing by 17% to $2.97 billion. Excluding REGEN-COV, revenues increased by 25%. GAAP diluted EPS was $8.61, and non-GAAP diluted EPS was $11.49. The company saw substantial U.S. sales growth for EYLEA and Dupixent worldwide.
First quarter 2022 revenues increased 17% to $2.97 billion versus first quarter 2021; excluding REGEN-COV, revenues increased 25%.
First quarter 2022 EYLEA U.S. net sales increased 13% to $1.52 billion versus first quarter 2021.
First quarter 2022 Dupixent global net sales increased 43% to $1.81 billion versus first quarter 2021.
First quarter 2022 GAAP diluted EPS of $8.61; non-GAAP diluted EPS of $11.49.
Revenue by Segment
Forward Guidance
The company's full year 2022 financial guidance includes GAAP R&D expenses between $3.270 billion and $3.500 billion, GAAP SG&A expenses between $1.890 billion and $2.030 billion, gross margin on net product sales between 89% and 91%, COCM expenses between $750 million and $830 million, capital expenditures between $630 million and $700 million, and an effective tax rate between 11% and 13%.
Positive Outlook
- GAAP R&D $3.270 billion–$3.500 billion
- SG&A $1.890 billion–$2.030 billion
- Gross margin on net product sales 89%–91%
- COCM $750 million–$830 million
- Effective tax rate (ETR)11%–13%
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...